Moderna stock surges 12.27 percent as cancer data near

Published on 09/22/2026 at 12:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock closed at USD 172.94 on September 21, 2026, after a 12.27 percent gain. Quarterly revenue reached USD 145 million, up 2.1 percent year over year.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) stock closed at USD 172.94 on the Nasdaq on September 21, 2026, gaining 12.27 percent from the prior session. The move followed fresh attention on the company's personalized cancer vaccine program and a new 52-week high of USD 176.86.

Cancer data set the next test

According to Digital Journal on September 21, 2026, Moderna said three abstracts on intismeran autogene had been accepted for presentation at the European Society for Medical Oncology Congress 2026. The program is an individualized mRNA-based neoantigen therapy being developed for melanoma alongside Merck's Keytruda.

The scheduled investor event on October 24, 2026 gives the market a defined checkpoint for the program. The same company announcement said the full Congress will run from October 23 through October 27, 2026, with Moderna's webcast planned for October 24.

Revenue beat estimates despite losses

Moderna generated USD 145.00 million in quarterly revenue, according to MarketBeat in its September 21, 2026 report. Revenue was 2.1 percent higher than in the same quarter a year earlier and exceeded the USD 102.93 million consensus estimate by USD 42.07 million.

The quarterly loss was USD 1.97 per share, compared with a consensus loss of USD 2.03 and a loss of USD 2.13 per share in the year-earlier period. The comparison shows an earnings beat of USD 0.06 per share, but the negative result keeps operating performance and cash use central to the valuation.

Stock trades above analyst average

Moderna traded as high as USD 176.86 on September 21, 2026, while volume reached 20,940,979 shares, according to the available Nasdaq market data. The session ended at USD 172.94, leaving the stock close to its new 52-week peak.

According to TIKR on September 22, 2026, 23 analysts had a mean price target of USD 120, compared with the September 21 close of USD 172.94. The target was USD 52.94 below the closing price, a gap of 30.6 percent, making the October oncology data a significant test of whether the recent valuation can be supported by clinical progress.

Nasdaq close remains the reference

Moderna stock closed at USD 172.94 on the Nasdaq on September 21, 2026, after a 12.27 percent daily gain. MarketBeat reported a market capitalization of USD 69.64 billion and a trading volume of 16,200,492 shares in its September 21 market snapshot.